| 刘小勇,向宸辉,陈胜龙,康 蓉,卢 芳.肾石通颗粒联合盐酸坦洛新缓释胶囊治疗输尿管下段结石的疗效观察[J].现代生物医学进展英文版,2018,(14):2718-2721. |
| 肾石通颗粒联合盐酸坦洛新缓释胶囊治疗输尿管下段结石的疗效观察 |
| Lower Ureteral Calculus: Curative Effect of Shenshitong Granules Combined with Tamsulosin Hydrochloride Sustained-Release Capsules |
| Received:September 03, 2017 Revised:September 27, 2017 |
| DOI：10.13241/j.cnki.pmb.2018.14.025 |
| 中文关键词: 肾石通颗粒 盐酸坦洛新缓释胶囊 输尿管结石 疗效 |
| 英文关键词: Shenshitong Granules Tamsulosin Hydrochloride Sustained-release Capsules Ureteral calculus Curative effect |
| 基金项目: |
|
| Hits: 530 |
| Download times: 406 |
| 中文摘要: |
| 摘要 目的：探讨肾石通颗粒联合盐酸坦洛新缓释胶囊治疗输尿管下段结石的临床疗效，为其临床应用提供参考资料。方法：选择189例自2013年6月至2016年6月在我院确诊为单侧输尿管下段结石患者随机分为对照组（n=93）和观察组（n=96），对照组给予肾石通颗粒治疗，观察组给予肾石通颗粒联合盐酸坦洛新缓释胶囊治疗。治疗2周后，观察两组患者的临床有效率、结石排出率、结石排出时间、肾绞痛发生率、肾绞痛视觉模拟量表（VAS）评分及不良反应发生率。结果：观察组临床总有效率为90.62%（87/96），高于对照组的77.42%（72/93）；观察组结石排出率为67.79%（67/96），高于对照组的53.76%（50/93）；观察组结石排出时间为 (7.15±2.67）d，少于对照组的 (10.47±3.23）d；观察组肾绞痛发生率为16.67%（16/96），低于对照组32.26%（30/93）；观察组VAS评分为（3.15±0.98）分，低于对照组的（4.37±1.25）分，以上比较差异均具有统计学意义（P<0.05）。观察组和对照组的不良反应发生率分别为14.58%（14/96）、12.90%（12/93），两组比较差异无统计学意义（P>0.05）。结论：在肾石通颗粒基础上加用盐酸坦洛新缓释胶囊可提高输尿管下段结石患者的临床有效率、结石排出率、缩短结石排出时间和减少肾绞痛的发生率。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical efficacy of Shenshitong Granules combined with Tamsulosin Hydrochloride Sus- tained-release Capsules in the treatment of lower ureteral calculus, and provide reference for clinical application. Methods: A total of 189 patients with unilateral lower ureteral calculus,who were diagnosed in the First Affiliated Hospital of Chengdu Medical College from June 2013 to June 2016, were selected and randomly divided into control group (n=93) and observation group (n=96). The control group was treated with Shenshitong Granules; the observation group, with Shenshitong Granules combined with Tamsulosin Hydrochloride Sustained-release Capsules. After two weeks of treatment, the clinical effective rate, calculus expulsion rate,calculus expulsion time, inci- dence of renal colic, visual analogue scale (VAS) scores and incidence rate of adverse reactions were compared between the two groups. Results: The clinical total effective rate[90.62% (87/96)] of the observation group was higher than that[77.42% (72/93)] of the control group. The calculus expulsion rate[67.79% (67/96)] of the observation group was higher than that[53.76% (50/93)] of the control group.The calculus expulsion time(7.15±2.67)d of the observation group was less than that (10.47±3.23)d of the control group. The incidence of renal colic[16.67% (16/96)] in the observation group was lower than that[32.26% (30/93)] of the control group. The VAS score(3.15±0.98) of the observation was lower than that(4.37±1.25) of the control group. The above differences were statistically significant (all P<0.05). The incidence of adverse reactions in the observation group and the control group were 14.58% (14/96) and 12.90% (12/93) re- spectively, there was no significant difference between the two groups (P>0.05). Conclusion: Shenshitong Granules combined with Tamsulosin Hydrochloride Sustained-release Capsules can increase clinical effective rate, alculus expulsion rate, shorten the calculus ex- pulsion time and reduce the incidence of renal colic in the treatment of patients with lower ureteral calculus. |
|
View Full Text
View/Add Comment Download reader |
| Close |
